Siemens Healthineers: UBS still a buyer

(CercleFinance.com) - UBS reiterates its 'buy' rating on Siemens Healthineers share, increasing its target price for them from E55 to E60, with the latter representing 13% upside potential for the German medical technology group's stock.


"2024 should bring ideal conditions for a re-rating with clean comps, inflecting margins, and a pick of catalysts", the broker summarises.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.